The Nottingham Haematology Group, encompasses both clinical and laboratory research. The clinical research has a pioneering interest in the development of peripheral blood stem cells for matched and unrelated donor transplantation. Acute myeloid leukaemia (AML) affects the myeloid-producing cells in the bone marrow. It is the most common acute leukaemia to affect adults and its incidence increases with age. Areas of particular interest in AML research include the role of the ABC drug transporter protein family, DNA damage and repair mechanisms, telomere maintenance, identification of factors that predispose to AML and understanding contributory factors underpinning minimal residual disease. The research aims to identify ways to maximise the therapeutic efficacy of existing drugs and to evaluate new treatments for AML. The University of Nottingham is consistently named as one of the most targeted universities by Britain's leading graduate employers and can offer students a head-start when it comes to their career.